Skip to main content Skip to search Skip to main navigation

ICH: ICH Q3C(R8) Guideline for Residual Solvents contains new PDEs

ICH published the revised version (Step 4) of the ICH Q3C(R8) Guideline on Impurities: Guideline for Residual Solvents on 22 April 2021.

The Permitted Daily Exposure (PDE) values for the following substances were added:  

  • 2-Methyltetrahydrofuran (50 mg/day) 
  • Cyclopentyl methyl ether (15 mg/day)  
  • Tertiary butyl alcohol (35 mg/day) 

The PDE values were developed by the relevant Expert Working Group (EWG). On 25 March 2020, ICH already published the document for public consultation under Step 2 (we reported). The values proposed then have been adopted as final and the Step 4 version has not been changed compared to the draft document. This allows implementation to take place in the ICH regions. This ICH process, which is conducted under "Step 5", concludes the revision. 

Toxicity details:  

  • Methyltetrahydrofuran was found to be non-genotoxic in a mutation assay with bacteria, human lymphocytes and rats. No data are available on carcinogenicity. Reproductive toxicity and repeated-dose toxicity were not observed. The product was classified in solvent class 3.  
  • For cyclopentyl methyl ether, no toxicity in humans was found. Likewise, no genotoxic potential was found. Again, no data are available on carcinogenicity. No statements could be made on reproductive and developmental toxicity on the basis of data available to date. The product was classified as a class 2 solvent.  
  • For tertiary butyl alcohol, no genotoxicity was found either. The data on carcinogenicity do not allow any precise conclusions to be drawn with regard to the effect on humans, while changes in the renal tubules were found in rats. No precise statements could be made on reproductive toxicity either, but moderate transient systemic toxicity was found in rats. The product was classified as a class 2 solvent.  

In a revision process, further PDE values are to be gradually added as new toxicological data for solvents become known. 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
Previous
Next